Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Maura N. Dickler's publication output changed over time?
ScholarIQpublication output · 2001–2018
Output grew100% over the shown period — from 1 works in 2001 to 2 in 2018.
1
1
1
1
1
1
2
2
2
200120052007200820132015201620172018
What are the most-cited papers on Maura N. Dickler?
ScholarIQmost cited works
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Kathy D. Miller, Molin Wang, Julie R. Gralow, Maura N. Dickler, Melody Cobleigh, Edith A. Perez, Tamara Shenkier, David Cella, Nancy E. Davidson
New England Journal of Medicine. 20073,066 CitationsOPEN ACCESS
Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer
Kathy D. Miller, Linnea Chap, Frankie A. Holmes, Melody Cobleigh, P. Kelly Marcom, Louis Fehrenbacher, Maura N. Dickler, Beth Overmoyer, James D. Reimann, Amy P. Sing, Virginia K. Langmuir, Hope S. Rugo
Journal of Clinical Oncology. 20051,310 CitationsOPEN ACCESS
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Pedram Razavi, Matthew T. Chang, Guotai Xu, Chaitanya Bandlamudi, Dara S. Ross, Neil Vasan, Yanyan Cai, Craig M. Bielski, Mark T.A. Donoghue, Philip Jonsson, Alexander Penson, Ronglai Shen, Fresia Pareja, Ritika Kundra, Sumit Middha, Michael L. Cheng, Ahmet Zehir, Cyriac Kandoth, Ruchi Patel, Kety Huberman, Lillian M. Smyth, Komal Jhaveri, Shanu Modi, Tiffany A. Traina, Chau T. Dang, Wen Zhang, Britta Weigelt, Bob T. Li, Marc Ladanyi, David M. Hyman, Nikolaus Schultz, Mark E. Robson, Clifford A. Hudis, Edi Brogi, Agnès Viale, Larry Norton, Maura N. Dickler, Michael F. Berger, Christine A. Iacobuzio–Donahue, Sarat Chandarlapaty, Maurizio Scaltriti, Jorge S. Reis‐Filho, David B. Solit, Barry S. Taylor, José Baselga
S25671836. 20181,022 CitationsOPEN ACCESS
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
Maura N. Dickler, Sara M. Tolaney, Hope S. Rugo, Javier Cortés, Véronique Dièras, Debra A. Patt, Hans Wildiers, Clifford A. Hudis, Joyce O’Shaughnessy, Esther Zamora, Denise A. Yardley, Martin Frenzel, Andrew Koustenis, José Baselga
Clinical Cancer Research. 2017687 CitationsOPEN ACCESS
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
Hope S. Rugo, R. Bryan Rumble, Erin Macrae, Debra L. Barton, Hannah Connolly, Maura N. Dickler, Lesley Fallowfield, Barbara Fowble, James N. Ingle, Mohammad Jahanzeb, Stephen Johnston, Larissa A. Korde, James Khatcheressian, Rita S. Mehta, Hyman B. Muss, Harold J. Burstein
Journal of Clinical Oncology. 2016651 CitationsOPEN ACCESS
Related on ScholarIQ
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Paper
Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer
Paper
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Paper
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
Paper
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
Paper
Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100
Paper